GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Syneos Health Inc (NAS:SYNH) » Definitions » Return-on-Tangible-Equity

Syneos Health (Syneos Health) Return-on-Tangible-Equity : Negative Tangible Equity% (As of Jun. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Syneos Health Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Syneos Health's annualized net income for the quarter that ended in Jun. 2023 was $3 Mil. Syneos Health's average shareholder tangible equity for the quarter that ended in Jun. 2023 was $-2,062 Mil. Therefore, Syneos Health's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2023 was Negative Tangible Equity%.

The historical rank and industry rank for Syneos Health's Return-on-Tangible-Equity or its related term are showing as below:

SYNH' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0
Current: Negative Tangible Equity

SYNH's Return-on-Tangible-Equity is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: -0.81 vs SYNH: Negative Tangible Equity

Syneos Health Return-on-Tangible-Equity Historical Data

The historical data trend for Syneos Health's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syneos Health Return-on-Tangible-Equity Chart

Syneos Health Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity

Syneos Health Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity - Negative Tangible Equity

Competitive Comparison of Syneos Health's Return-on-Tangible-Equity

For the Diagnostics & Research subindustry, Syneos Health's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syneos Health's Return-on-Tangible-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Syneos Health's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Syneos Health's Return-on-Tangible-Equity falls into.



Syneos Health Return-on-Tangible-Equity Calculation

Syneos Health's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2022 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=266.497/( (-2397.527+-2083.38 )/ 2 )
=266.497/-2240.4535
=Negative Tangible Equity %

Syneos Health's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jun. 2023 )  (Q: Mar. 2023 )(Q: Jun. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jun. 2023 )  (Q: Mar. 2023 )(Q: Jun. 2023 )
=3.172/( (-2097.442+-2026.275)/ 2 )
=3.172/-2061.8585
=Negative Tangible Equity %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jun. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Syneos Health  (NAS:SYNH) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Syneos Health Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Syneos Health's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Syneos Health (Syneos Health) Business Description

Traded in Other Exchanges
N/A
Address
1030 Sync Street, Morrisville, NC, USA, 27560-5468
Syneos is a global contract research and outsourced commercialization organization that provides services to pharmaceutical and biotechnology firms. Its clinical solutions segment offers early- to late-stage clinical trial support that ranges from specialized staffing models to strategic partnerships that oversee nearly all aspects of a drug program, while the company's commercialization solutions includes outsourced sales, consulting, public relations, and advertising services.
Executives
Michael J. Bonello officer: Chief Financial Officer 4130 PARKLAKE AVENUE, SUITE 400, RALEIGH NY 27612
Stanford Rudnick officer: See remarks C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560-5468
Christian Tucat officer: Chief Business Officer C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560-5468
Michael Lee Brooks officer: See remarks C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560
Jonathan Olefson officer: General Counsel & Corp Secty C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560
Michelle Keefe officer: Pres., Commercial Solutions C/O SYNEOS HEALTH,INC., 1030 SYNC STREET, MORRISVILLE NC 27560
Jason M. Meggs officer: Chief Financial Officer C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560
Donna Hildebrand Kralowetz officer: SVP, Chief Accounting Officer C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560
Matthew E. Monaghan director ONE INVACARE WAY, ELYRIA OH 44035
Alfonso G Zulueta director 4925 INDIANA AVE, LISLE IL 60532
Barbara W. Bodem director C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Linda S Harty director MEDTRONIC PLC, 710 MEDTRONIC PARKWAY NE, LC-150, MINNEAPOLIS MN 55432
Alistair Macdonald officer: Chief Operating Officer C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560
David S. Wilkes director ONE BAXTER PARKWAY, DEERFIELD IL 60015
Advent International Corp/ma 10 percent owner 800 BOYLSTON STREET SUITE 3300, BOSTON MA 02199

Syneos Health (Syneos Health) Headlines

From GuruFocus